Etiology of myasthenia gravis: innate immunity signature in pathological thymus

Autoimmun Rev. 2013 Jul;12(9):863-74. doi: 10.1016/j.autrev.2013.03.010. Epub 2013 Mar 25.

Abstract

Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction (NMJ), whose clinical hallmark is muscle weakness and early fatigability. The main target of autoimmunity in MG is the acetylcholine receptor (AChR) located in the NMJ. It is now widely accepted that the thymus is probably the prime site of autoimmunity development and maintenance in AChR-positive MG patients; however, the exact mechanisms triggering and perpetuating the intra-thymic autoimmune response to AChR are still unknown. As with many autoimmune diseases, MG has a multifactorial etiology, resulting from complex interactions between genetic and environmental factors, as fully described in this review. Among environmental factors, viral infections could play a central role in autoimmunity, mainly through the induction of dysregulated Toll-like receptor (TLR)-mediated innate immune responses, which can lead to inflammation and adaptive autoimmune response. Growing evidence of chronic inflammation, TLR activation, and persistent viral infections in the thymus of MG patients, strongly supports the hypothesis that, in the context of a genetic susceptible background, the intrathymic innate immune responses to pathogen infections might contribute to MG etiology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Immunity, Innate
  • Myasthenia Gravis / genetics
  • Myasthenia Gravis / immunology*
  • Myasthenia Gravis / pathology
  • Neuromuscular Junction / immunology
  • Neuromuscular Junction / pathology
  • Receptors, Cholinergic / immunology
  • Thymus Gland / immunology
  • Toll-Like Receptors / immunology

Substances

  • Receptors, Cholinergic
  • Toll-Like Receptors